Structure Therapeutics (NASDAQ:GPCR – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Valuation and Earnings
This table compares Structure Therapeutics and Oncobiologics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Structure Therapeutics | N/A | N/A | -$141.20 million | ($0.87) | -59.41 |
| Oncobiologics | $1.35 million | 175.32 | -$62.42 million | ($1.17) | -1.44 |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Structure Therapeutics and Oncobiologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Structure Therapeutics | 2 | 1 | 12 | 3 | 2.89 |
| Oncobiologics | 1 | 5 | 1 | 0 | 2.00 |
Structure Therapeutics presently has a consensus price target of $110.55, suggesting a potential upside of 113.86%. Oncobiologics has a consensus price target of $6.50, suggesting a potential upside of 284.62%. Given Oncobiologics’ higher possible upside, analysts plainly believe Oncobiologics is more favorable than Structure Therapeutics.
Profitability
This table compares Structure Therapeutics and Oncobiologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Structure Therapeutics | N/A | -24.91% | -23.67% |
| Oncobiologics | N/A | N/A | -291.28% |
Risk & Volatility
Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.
Insider & Institutional Ownership
91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Structure Therapeutics beats Oncobiologics on 7 of the 13 factors compared between the two stocks.
About Structure Therapeutics
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
